2,4-difluoro-5-[(4R)-3-[1-[[6-(2-fluoro-4-methylsulfonyl-phenoxy)-2-methyl-3-pyridyl]methyl]-4-piperidyl]-2-oxo-4-phenyl-imidazolidin-1-yl]benzamide | 1344151-83-2

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: 2,4-difluoro-5-[(4R)-3-[1-[[6-(2-fluoro-4-methylsulfonyl-phenoxy)-2-methyl-3-pyridyl]methyl]-4-piperidyl]-2-oxo-4-phenyl-imidazolidin-1-yl]benzamide
• 英文别名: 2,4-difluoro-5-[(4R)-3-[1-[[6-(2-fluoro-4-methylsulfonylphenoxy)-2-methylpyridin-3-yl]methyl]piperidin-4-yl]-2-oxo-4-phenylimidazolidin-1-yl]benzamide
• CAS: 1344151-83-2
• 化学式: C₃₅H₃₄F₃N₅O₅S
• 分子量: 693.747
• InChiKey: DGZQCHPGVIUVFH-HKBQPEDESA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.3
• 重原子数：
  49
• 可旋转键数：
  9
• 环数：
  6.0
• sp3杂化的碳原子比例：
  0.29
• 拓扑面积：
  135
• 氢给体数：
  1
• 氢受体数：
  10

反应信息

• 作为产物：
  描述：

  Boc-D-苯甘氨醇 在 盐酸 、 三乙酰氧基硼氢化钠 、 1,8-二氮杂双环[5.4.0]十一碳-7-烯 、 三乙胺 作用下， 以 1,4-二氧六环 、 二氯甲烷 、 甲苯 为溶剂， 反应 2.0h， 生成 2,4-difluoro-5-[(4R)-3-[1-[[6-(2-fluoro-4-methylsulfonyl-phenoxy)-2-methyl-3-pyridyl]methyl]-4-piperidyl]-2-oxo-4-phenyl-imidazolidin-1-yl]benzamide
  参考文献：
  名称：

  Discovery of a novel series of cyclic urea as potent CCR5 antagonists

  摘要：

  A novel series of cyclic urea-based CCR5 antagonists was designed aiming to resolve instability issue in the fasted simulated intestinal fluid (FSIF) associated with the acyclic urea moiety in 1. This class of CCR5 compounds demonstrated high antiviral activities against HIV-1 infection in both HOS and PBL assays. Further evaluation of these compounds indicated that 16-R not only substantially enhanced its stability, but also exhibited excellent pharmacokinetics properties. (C) 2011 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2011.08.096

文献信息

• Discovery of a novel series of cyclic urea as potent CCR5 antagonists
  作者：Maosheng Duan、Wieslaw M. Kazmierski、Matt Tallant、Jung Ho Jun、Mark Edelstein、Rob Ferris、Dan Todd、Pat Wheelan、Zhiping Xiong

  DOI：10.1016/j.bmcl.2011.08.096

  日期：2011.11

  A novel series of cyclic urea-based CCR5 antagonists was designed aiming to resolve instability issue in the fasted simulated intestinal fluid (FSIF) associated with the acyclic urea moiety in 1. This class of CCR5 compounds demonstrated high antiviral activities against HIV-1 infection in both HOS and PBL assays. Further evaluation of these compounds indicated that 16-R not only substantially enhanced its stability, but also exhibited excellent pharmacokinetics properties. (C) 2011 Elsevier Ltd. All rights reserved.